A Phase1 Interventional Sequential Single Site Study to Characterize the Effectiveness of Oral KAE609 in Reducing Asexual & Sexual Blood-stage P. Falciparum Following Inoculation in Healthy-volunteers & Subsequent Infectivity to Mosquitoes

Trial Profile

A Phase1 Interventional Sequential Single Site Study to Characterize the Effectiveness of Oral KAE609 in Reducing Asexual & Sexual Blood-stage P. Falciparum Following Inoculation in Healthy-volunteers & Subsequent Infectivity to Mosquitoes

Discontinued
Phase of Trial: Phase I

Latest Information Update: 19 Sep 2016

At a glance

  • Drugs Cipargamin (Primary) ; Piperaquine
  • Indications Falciparum malaria
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 02 Sep 2016 Status changed from completed to discontinued.
    • 19 Jul 2016 Status changed from discontinued to completed.
    • 30 Dec 2015 According to ClinicalTrials.gov record, status changed from recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top